查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1195547

消融設備市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Ablation Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

消融設備市場預計在預測期內 (2023-2028) 的複合年增長率為 10.4%。

由於 COVID-19 大流行，醫療保健系統面臨著巨大挑戰。 在 COVID-19 流行期間，大多數慢性病護理被認為是非緊急護理，所有門診護理都被推遲或限制，以降低病毒傳播的風險。 根據 2022 年 5 月發表在 Authorea 上的一篇論文“在 COVID-19 大流行期間導管消融相關不良事件的報告率下降”，報告的缺陷從 2019-2020 年到 2020-2021 年觀察到具有統計學意義的減少。 本文調查了美國食品和藥物管理局製造商和用戶設施設備的經驗，以確定與經皮心臟消融導管相關的房顫治療失敗、經皮心臟消融導管治療心房顫動相關的失敗以及心房撲動的治療顯示，本次疫情期間經皮心臟消融導管相關損傷報告率明顯下降。 在 COVID-19 大流行期間，所有非緊急擇期手術都已暫停，導致與往年相比，在此期間進行的消融手術數量非常少。 因此，COVID-19 大流行對市場的增長產生了重大影響。

癌症、心血管疾病和其他眼科、婦科和泌尿科疾病等主要慢性病在全球範圍內呈上升趨勢，推動了消融設備市場的增長。 此外，隨著風險的增加，已經出現了有效治療慢性病患者的有效手術方式。 慢性病的日益流行在醫療保健中發揮著重要作用。

由於慢性病的增加，越來越多的因素也在提高消融設備領域的市場份額。 例如，癌症是全世界死亡的主要原因之一，預計到 2020 年將導致約 1000 萬人死亡。 根據 GLOBOCAN 2020 報告，2020 年全球癌症患者總數約為 19,292,789 人。 據估計，到 2040 年將增加到 28,887,940 人。 根據國際糖尿病聯合會《糖尿病地圖集第十版2021》，2021年全球約有5.37億成年人被診斷患有糖尿病，到2030年將達到6.43億。到2045年，這一數字預計將增加到7.83億。 全球慢性病的增加預計將推動研究目標市場的增長。

一些專注於創新消融設備的研發研究也在推動血流設備測量市場的增長。 例如，2021 年 5 月，Acutus Medical 啟動了一項前瞻性、多中心、非隨機的國際臨床試驗，旨在證明 AcQBlate 力傳感系統的安全性和性能。 AcQBlate 力傳感系統是用於心律失常的電生理標測和射頻消融的完整且差異化的解決方案。 這項研究將側重於可及肺靜脈的導管消融，最終目標是為每條肺靜脈建立有針對性的電隔離，預計將於 2024 年 1 月完成。 預計消融設備開發研究的增加將在預測期內推動消融設備市場的增長。

消融領域主要參與者的不斷發展也刺激了市場增長。 例如，2021 年 11 月，Hologic 推出了 NovaSure V5，這是美國研究最多和最值得信賴的子宮內膜消融（ GEA ）設備。 此類設備的研究和開發不斷增加，預計將推動市場的增長。

全球對消融設備日益增長的需求預計將推動消融設備市場的增長。 然而，該設備的高成本、嚴格的法規和消融設備的低意識可能會阻礙市場增長。

消融設備市場趨勢

在消融設備市場，癌症治療領域預計將佔據主要市場份額。

癌症治療是消融設備市場的一個主要部分。 全球癌症患者數量的增加也刺激了消融設備市場的發展。 世界癌症研究基金會國際組織在其 2022 年 3 月更新的全球癌症數據中指出，到 2020 年，全球估計將有 1810 萬癌症患者。 其中，男性為 930 萬，女性為 880 萬。 多年來病例數量的顯著增加極大地促進了癌症手術的增加，以進行有效的治療研究，這很可能在預測期內推動消融設備市場的增長。

根據 2021 年 2 月更新的 RadiologyInfo.org 文章，射頻消融術 (RFA) 是一種微創癌症治療方法，它使用一種圖像引導技術，利用熱量來破壞癌細胞。我們正在招聘。 RFA利用超聲波、CT（計算機斷層掃描）、MRI（磁共振成像）等將針狀電極引導至癌性腫瘤，通過電極，高頻電流通過放置在其上的接地墊身體，它會產生集中的熱量，破壞電極周圍的癌細胞。 該文章還表明，射頻和微波消融是癌症治療中最常用的消融方式。

此外，多個市場參與者正在關注癌症市場的消融設備。 例如，2022 年 5 月，Avenda Health 的 iQuest 在 2022 年美國泌尿外科協會年會上宣布，一項回顧性研究表明，與傳統治療方案相比，iQuest 將腫瘤包封率從 56% 提高到 80%。 2021 年 5 月，美國食品和藥物管理局宣布了一項由總部位於加利福尼亞州的軟件和醫療設備公司 Avenda Health 開發的前列腺癌治療方法，該方法使用人工智能 (AI) 和微創技術來改善癌癥結果。該技術被指定為突破性設備. Avenda Health 焦點治療系統是一種支持人工智能（ AI ）的焦點治療系統，正在開髮用於通過局部麻醉治療局部前列腺癌。 除了依賴於大型圖像和病理數據庫的基於人工智能的邊緣預測算法外，該設備還使用激光和獨特的光學和熱傳感器來精確定位和治療前列腺腫瘤。 這種靶向消融設備的目的是在不損害其他身體功能的情況下，最大限度地減少對健康組織的影響。 預計此類消融設備的研發將在預測期內推動市場增長。

北美將佔據很大的市場份額，預計在預測期內（2022 年至 2027 年）也將如此。

在消融設備製造中越來越多地採用先進技術和系統，以及消融設備研究方面的技術進步預計將推動北美地區的市場增長。 人們對市場上創新消融設備治療的可用性的高度認識有助於該地區的高市場增長。

北美地區越來越多的慢性病患者正在刺激消融設備市場的增長。 癌症是美國十大死因之一。 根據 GLOBOCAN 2020 報告，2020 年美國癌症患者總數將約佔 2,281,658 人。 據估計，到 2040 年將增加到 3,123,452。 根據 2022 年 1 月更新的國家糖尿病統計報告，美國已知約有 3730 萬人患有糖尿病，約有 9600 萬成年人處於糖尿病前期。 國家腎臟基金會 2021 年估計，美國約有 3700 萬成年人患有慢性腎病。 美國疾病控制與預防中心 2020 年的一份報告發現，約有 1570 萬美國人患有慢性下呼吸道疾病。 患有慢性病的大量人口以及對消融設備以促進此類疾病的診斷和治療的需求不斷增加，預計將推動消融設備市場的增長。

該地區創新消融設備的不斷發展也推動了市場的增長。 例如，2020 年 7 月，美國食品和藥物管理局授予了一項突破性設備稱號，用於經支氣管微波消融技術，該技術使用了強生醫療器械公司子公司 Ethicon 開發的機器人輔助支氣管鏡。我在這裡。 消融設備的此類技術創新和不斷增加的監管批准有望在預測期內推動消融設備市場的增長。

因此，眾所周知，對消融設備不斷增長的需求以及對醫療行業投資的增加將推動該地區的市場增長。

消融設備市場競爭對手分析

全球消融設備市場競爭適中，由幾家主要參與者組成。Abbott、AngioDynamics, Inc、AtriCure, Inc、Boston Scientific Corporation、BTG plc、Conmed Corporation、Johnson and Johnson、Medtronic PLC、Olympus Corporation、Smith &Nephew PLC諸如此類的公司在消融設備市場中佔有相當大的市場份額。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 慢性病增加
    • 技術進步
    • 下一代消融產品和技術的出現
  • 市場製約因素
    • 設備成本高
    • 認知度低，監管嚴格
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 按設備技術
    • 高頻設備
    • 激光/光學燒蝕
    • 超聲波設備
    • 冷凍消融設備
    • 其他設備
  • 通過申請
    • 癌症治療
    • 心血管疾病治療
    • 眼科治療
    • 婦科治療
    • 泌尿外科治療
    • 整容手術
    • 其他
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 其他
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Abbott Laboratories
    • Alcon Laboratories
    • AngioDynamics, Inc.
    • AtriCure, Inc.
    • Bausch & Lomb Incorporated
    • Biotronik
    • Boston Scientific Corporation
    • Conmed Corporation
    • Johnson and Johnson
    • Medtronic PLC
    • Olympus Corporation
    • Smith & Nephew PLC

第7章 市場機會與今後動向

簡介目錄
Product Code: 67243

The Ablation Devices Market is projected to register a CAGR of 10.4% during the forecast period (2023 - 2028).

The healthcare system has witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to ​reduce the risk of viral transmission, as most chronic therapies were regarded as non-urgent. An article titled "Decrease in Reported Rates of Catheter Ablation-Related Adverse Events During the COVID-19 Pandemic" published in the journal of Authorea in May 2022 indicated that there was a statistically significant drop in reported malfunctions from the year 2019 - 2020 to 2020 - 2021. The article examined the United States Food and Drug Administration Manufacturer and User Facility Device Experience and illustrated that there were significant decreases in reported rates of malfunctions associated with cardiac ablation percutaneous catheters, malfunctions associated with cardiac ablation percutaneous catheters for the treatment of atrial fibrillation, and injuries associated with cardiac ablation percutaneous catheters for the treatment of atrial flutter during the pandemic. Due to the suspension of all non-urgent elective surgical operations during the COVID-19 pandemic, the number of ablation surgeries performed during the period is very less compared to that of the previous year. Thus, the COVID-19 pandemic significantly impacted the growth of the market.

The major chronic diseases such as cancer, cardiovascular diseases, and other ophthalmologic, gynecological, and urological diseases are on the rise all over the world, which is adding to the growth of the ablation devices market.​With increasing risks, there are also effective surgical therapies that lead to the efficient treatment of patients suffering from chronic illness. The rise in the number of chronic disease cases plays an important role in healthcare.

In addition, the growing number of factors attributing to the rise in chronic disease is increasing the market share for the ablation devices segment. For instance, cancer is one of the leading causes of death all around the world, accounting for around 10 million deaths in 2020. According to the GLOBOCAN 2020 report, the total number of people in the world affected by cancer in 2020 accounts for around 19,292,789 cases. The number is estimated to rise to 28,887,940 cases by 2040. ​Also, according to the International Diabetes Federation Diabetes Atlas Tenth edition 2021, in 2021, around 537 million adults all over the world were found to have diabetes, with the numbers projected to grow to 643 million by 2030 and 783 million by 2045. The rise in the number of chronic diseases all over the world is expected to propel the growth of the studied market.

Several research and development studies focusing on innovative Ablation Devices are also adding to the growth of the blood flow device measurement market. For instance, in May 2021, Acutus Medical initiated a prospective, multi-center, non-randomized global clinical study designed to demonstrate the safety and performance of the AcQBlate Force Sensing System. AcQBlate Force Sensing System is a complete and differentiated solution for the electrophysiologic mapping and radiofrequency ablation of cardiac arrhythmias. The study focuses on the catheter ablation of accessible pulmonary veins with the endpoint of creating electrical isolation for each targeted vein and is expected to be completed by January 2024. The increasing research in the development of ablation devices is expected to boost the growth of the ablation devices market in the forecast period.

The increasing developments made among the key players in the ablation segment are also adding to the growth of the market. For instance, in November 2021, Hologic, Inc. launched the NovaSure V5 global endometrial ablation (GEA) device, the most studied and trusted endometrial ablation procedure in the United States. The rise in the research and development of such devices is expected to boost market growth.

The increase in the necessity of ablation devices around the world is expected to propel the growth of the ablation devices market.​ However, the high cost of the devices and the strict regulations, coupled with the lack of awareness about ablation devices, are likely to hinder the market growth.

Ablation Devices Market Trends

The Cancer Treatment Segment is Expected to Hold a Major Market Share in the Ablation Devices Market.

Cancer treatment holds the major segment in the ablation devices market. The rising number of cancer cases around the world is also adding to the developments in the ablation devices market. The World Cancer Research Fund International, in its Worldwide Cancer Data updated in March 2022, indicated that there were an estimated 18.1 million cancer cases around the world in 2020. Of these, 9.3 million cases were in men and 8.8 million in women. The large increase in the number of cases over the years is majorly contributing to the increase in cancer surgical therapies for efficient treatment studies, which in turn will propel the growth of the ablation devices market in the forecast period.

According to an article by the RadiologyInfo.org updated in February 2021, radiofrequency ablation (RFA), a minimally invasive treatment for cancer, employs an image-guided technique to apply heat to destroy cancer cells. RFA uses ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) to guide a needle electrode into a cancerous tumor and passes high-frequency electrical currents through the electrode to ground pads placed on the body, thereby creating focused heat that destroys the cancer cells surrounding the electrode. The article also suggested that radio frequency and microwave ablations are the most commonly used ablation treatment methods for cancer therapy.

Several market players are also focusing on ablation devices for the cancer market. For instance, in May 2022, Avenda Health's iQuest was presented at the 2022 American Urological Association annual meeting, where the retrospective study indicated that iQuest improved tumor encapsulation over conventional treatment planning from 56 percent to 80 percent. The United States Food and Drug Administration awarded the Breakthrough Device designation for the technology in May 2021 to treat prostate cancer developed by the California-based software and medical device company Avenda Health to improve cancer outcomes through artificial intelligence (AI) and minimally invasive technologies. The Avenda Health Focal Therapy System is artificial intelligence (AI)-enabled focal therapy system being developed to treat localized prostate cancer under local anesthesia. Along with AI-based margin prediction algorithms, which rely on a large database of imaging and pathology, the device uses a laser and a proprietary optical and thermal sensor to precisely target and treat just the prostate tumor. The goal of this targeted ablation device is to minimize the impact on healthy tissues without compromising other bodily functions. Such research and developments in ablation devices are expected to propel market growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period (2022 - 2027).

The rise in the adoption of highly advanced techniques and systems in the manufacturing of ablation devices and the technological advancements made in ablation device studies is expected to boost the growth of the market in the North American region. The high awareness among the population on the availability of innovative ablation device therapies in the market contributes to the high market growth in the region.

The rising number of chronic disease cases in the North American region is adding to the growth of the Ablation Devices market.​ Cancer is one of the top ten leading causes of death in the United States. According to the GLOBOCAN 2020 report, the total number of people in the United States affected by cancer in 2020 accounts for around 2,281,658 cases. The number is estimated to rise to 3,123,452 cases by 2040. ​According to the National Diabetes Statistics Report, updated in January 2022, around 37.3 million people in the United States were found to have diabetes; around 96 million adults were found to have pre-diabetes. ​The National Kidney Foundation 2021 has estimated that about 37 million adults in the United States have chronic kidney diseases. ​A report by the Centers for Disease Prevention and Control in 2020 showed that around 15.7 million Americans are affected by chronic lower respiratory Disease.​The large population affected by chronic diseases and the increase in the necessity of ablation devices for the ease of diagnosis and treatment of such diseases is expected to propel the growth of the ablation devices market.​

Also, the rise in the development of innovative ablation devices in the region is also adding to the growth of the market. For instance, in July 2020, the United States Food and Drug Administration granted Breakthrough Device Designation for transbronchial microwave ablation technology using robotic-assisted bronchoscopy, developed by Ethicon, a part of the Johnson & Johnson Medical Devices Company. Such innovations in the ablation devices and the rise in approval by regulatory bodies are likely to boost the growth of the ablation devices market over the forecast period.

Thus the increasing necessity for ablation devices coupled with increasing investment in the health care department is known to propel the growth of the market in this region.

Ablation Devices Market Competitor Analysis

The global ablation device market is moderately competitive and consists of a few major players. Companies like Abbott, AngioDynamics, Inc., AtriCure, Inc., Boston Scientific Corporation, BTG plc, Conmed Corporation, Johnson and Johnson, Medtronic PLC, Olympus Corporation, Smith & Nephew PLC, among others, hold a substantial market share in the Ablation Devices market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in the Prevalence of Chronic Diseases
    • 4.2.2 Technological Advancements
    • 4.2.3 Emergence of Next-generation Ablation Products and Technology
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Device
    • 4.3.2 Lack of Awareness and Stringent Regulations
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Device Technology
    • 5.1.1 Radiofrequency Devices
    • 5.1.2 Laser/Light Ablation
    • 5.1.3 Ultrasound Devices
    • 5.1.4 Cryoablation Devices
    • 5.1.5 Other Devices
  • 5.2 By Application
    • 5.2.1 Cancer Treatment
    • 5.2.2 Cardiovascular Disease Treatment
    • 5.2.3 Ophthalmologic Treatment
    • 5.2.4 Gynecological Treatment
    • 5.2.5 Urological Treatment
    • 5.2.6 Cosmetic Surgery
    • 5.2.7 Others
  • 5.3 By End-Users
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Alcon Laboratories
    • 6.1.3 AngioDynamics, Inc.
    • 6.1.4 AtriCure, Inc.
    • 6.1.5 Bausch & Lomb Incorporated
    • 6.1.6 Biotronik
    • 6.1.7 Boston Scientific Corporation
    • 6.1.8 Conmed Corporation
    • 6.1.9 Johnson and Johnson
    • 6.1.10 Medtronic PLC
    • 6.1.11 Olympus Corporation
    • 6.1.12 Smith & Nephew PLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS